# US 2023/0055408 A1 · Anti-cea antibody-exatecan analog conjugate and pharmaceutical use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0055408 A1
- Document ID: US20230055408A1
- Status: Published application
- Kind: A1
- Application number: 17/785,373
- Filed: 2020-12-15
- Published: 2023-02-23
- Earliest claimed: 2019-12-16
- Assignees: Jiangsu Hengrui Medicine Co., Ltd.; Shanghai Hengrui Pharmaceutical Co., Ltd.
- Applicants: Jiangsu Hengrui Medicine Co., Ltd.; Shanghai Hengrui Pharmaceutical Co., Ltd.
- Inventors: Hua YING; Langyong MAO; Sijia WANG
- Web page: https://patentgrep.com/patent/US20230055408A1

## CPC

- A61K 47/65: Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
- A61K 47/545: {Heterocyclic compounds (A61K47/558 takes precedence)}
- A61K 47/68037: {the drug being a camptothecin [CPT] or derivatives}
- A61K 47/6853: {Carcino-embryonic antigens}
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- C07K 16/3007: {Carcino-embryonic Antigens}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/90: characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

An anti-CEA antibody-exatecan analog conjugate and a pharmaceutical use thereof. Specifically, the anti-CEA antibody-exatecan analog conjugate is as shown in general formula (Pc-L-Y-D), wherein Pc is an anti-CEA antibody or an antigen-binding fragment thereof; L is a linker unit; Y is selected from —O—(CRaRb)m—CR1R2—C(O)—, —O—CR1R2—(CRaRb)m—, —O—CR1R2—, —NH—(CRaRb)m—CR1R2—C(O)—, and —S—(CRaRb)m—CR1R2—C(O); and n is a decimal or integer from 1 to 10.

## Claims

### Claim 1

An antibody drug conjugate, comprising: an anti-CEA antibody or an antigen-binding fragment thereof conjugated to a toxin drug optionally by a linker, wherein the anti-CEA antibody or the antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region of the antibody, wherein:
i) the HCDR1 and the HCDR3 of the heavy chain variable region are identical to a HCDR1 and a HCDR3 of a heavy chain variable region set forth in SEQ ID NO: 9, and the HCDR2 of the heavy chain variable region is identical to a HCDR2 of the heavy chain variable region set forth in SEQ ID NO: 9 or differs therefrom by one amino acid; the LCDR1, the LCDR2 and the LCDR3 of the light chain variable region are identical to a LCDR1, a LCDR2 and a LCDR3 of a light chain variable region set forth in SEQ ID NO: 10:
ii) a HCDR1 and a HCDR3 of the heavy chain variable region are identical to a HCDR1 and a HCDR3 of a heavy chain variable region set forth in SEQ ID NO: 7, and a HCDR2 of the heavy chain variable region is identical to a HCDR2 of the heavy chain variable region set forth in SEQ ID NO: 7 or differs therefrom by one amino acid; a LCDR1, a LCDR2 and a LCDR3 of the light chain variable region are identical to a LCDR1, a LCDR2 and a LCDR3 of a light chain variable region set forth in SEQ ID NO: 8;
iii) the HCDR1, the HCDR2 and the HCDR3 of the heavy chain variable region are identical to an HCDR1, an HCDR2 and an HCDR3 of a heavy chain variable region set forth in SEQ ID NO: 11; the LCDR1, the LCDR2 and the LCDR3 of the light chain variable region are identical to a LCDR1, a LCDR2 and a LCDR3 of a light chain variable region set forth in SEQ ID NO: 12; or
iv) the HCDR1 and the HCDR3 of the heavy chain variable region are identical to a HCDR1 and a HCDR3 of a heavy chain variable region set forth in SEQ ID NO: 13, and the HCDR2 of the heavy chain variable region is identical to a HCDR2 of the heavy chain variable region set forth in SEQ ID NO: 13 or differs therefrom by one amino acid; the LCDR1 and the LCDR3 of the light chain variable region are identical to a LCDR1 and a LCDR3 of a light chain variable region set forth in SEQ ID NO: 14, and the LCDR2 of the light chain variable region is identical to a LCDR2 of the light chain variable region set forth in SEQ ID NO: 14 or differs therefrom by one amino acid.

### Claim 2 (depends on 1)

The antibody drug conjugate according to claim 1, wherein the anti-CEA antibody or the antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region, wherein:
(v) the heavy chain variable region comprises a HCDR1, a HCDR2 and a HCDR3 set forth in SEQ ID NO: 21, SEQ ID NO: 22 and SEQ ID NO: 23, respectively, and the light chain variable region comprises a LCDR1, a LCDR2 and a LCDR3 set forth in SEQ ID NO: 24, SEQ ID NO: 25 and SEQ ID NO: 26, respectively; or the heavy chain variable region comprises a HCDR1, a HCDR2 and a HCDR3 set forth in SEQ ID NO: 21, SEQ ID NO: 47 and SEQ ID NO: 23, respectively, and the light chain variable region comprises a LCDR1, a LCDR2 and a LCDR3 set forth in SEQ ID NO: 24, SEQ ID NO: 25 and SEQ ID NO: 26, respectively:
(vi) the heavy chain variable region comprises a HCDR1, a HCDR2 and a HCDR3 set forth in SEQ ID NO: 15, SEQ ID NO: 16 and SEQ ID NO: 17, respectively, and the light chain variable region comprises a LCDR1, a LCDR2 and a LCDR3 set forth in SEQ ID NO: 18, SEQ ID NO: 19 and SEQ ID NO: 20, respectively; or the heavy chain variable region comprises an HCDR1, a HCDR2 and a HCDR3 set forth in SEQ ID NO: 15, SEQ ID NO: 38 and SEQ ID NO: 17, respectively, and the light chain variable region comprises a LCDR1, a LCDR2 and a LCDR3 set forth in SEQ ID NO: 18, SEQ ID NO: 19 and SEQ ID NO: 20, respectively;
(vii) the heavy chain variable region comprises n HCDR1, a HCDR2 and a HCDR3 set forth in SEQ ID NO: 27, SEQ ID NO: 28 and SEQ ID NO: 29, respectively, and the light chain variable region comprises a LCDR1, a LCDR2 and a LCDR3 set forth in SEQ ID NO: 30, SEQ ID NO: 31 and SEQ ID NO: 32, respectively; or
(viii) the heavy chain variable region comprises a HCDR1 and a HCDR3 set forth in SEQ ID NO: 33 and SEQ ID NO: 34, respectively, and a HCDR2 set forth in SEQ ID NO: 16 or SEQ ID NO: 38; the light chain variable region comprises a LCDR1 and a LCDR3 set forth in SEQ ID NO: 35 and SEQ ID NO: 37, respectively, and a LCDR2 set forth in SEQ ID NO: 36 or SEQ ID NO: 64.

### Claim 3 (depends on 1)

The antibody drug conjugate according to claim 1, wherein the anti-CEA antibody is a murine antibody, a chimeric antibody or a humanized antibody.

### Claim 4 (depends on 1)

The antibody drug conjugate according to claim 1, wherein the anti-CEA antibody or the antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region, wherein:
(a) the heavy chain variable region has an amino acid sequence set forth in SEQ ID NO: 9, or an amino acid sequence having at least 90% identity to the amino acid sequence set forth in SEQ ID NO: 9; and/or the light chain variable region has an amino acid sequence set forth in SEQ ID NO: 10, or an amino acid sequence having at least 90% identity to the amino acid sequence set forth in SEQ ID NO: 10: or
(b) the heavy chain variable region has an amino acid sequence set forth in SEQ ID NO: 7, or an amino acid sequence having at least 90% identity to the amino acid sequence set forth in SEQ ID NO: 7; and/or the light chain variable region has an amino acid sequence set forth in SEQ ID NO: 8, or an amino acid sequence having at least 90% identity to the amino acid sequence set forth in SEQ ID NO: 8; or
(c) the heavy chain variable region has an amino acid sequence set forth in SEQ ID NO: 11, or an amino acid sequence having at least 90% identity to the amino acid sequence set forth in SEQ ID NO: 11; and/or the light chain variable region has an amino acid sequence set forth in SEQ ID NO: 12, or an amino acid sequence having at least 90% identity to the amino acid sequence set forth in SEQ ID NO: 12; or
(d) the heavy chain variable region has an amino acid sequence set forth in SEQ ID NO: 13, or an amino acid sequence having at least 90% identity to the amino acid sequence set forth in SEQ TD NO: 13; and/or the light chain variable region has an amino acid sequence set forth in SEQ ID NO: 14, or an amino acid sequence having at least 90 identity to the amino acid sequence set forth in SEQ ID NO: 14.

### Claim 5 (depends on 1)

The antibody drug conjugate according to claim 1, wherein the anti-CEA antibody or the antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region, wherein:
(e) the heavy chain variable region has an amino acid sequence set forth in SEQ ID NO: 48, 49, 50, 51 or 52, or an amino acid sequence having at least 90% identity to any one amino acid sequence set forth in SE ID NO: 48, 49, 50, 51 or 52; and/or the light chain variable region has an amino acid sequence set forth in SEQ ID NO: 53, 54 or 55, or an amino acid sequence having at least 90% identity to any one amino acid sequence set forth in SEQ TD NO: 53, 54 or 55; or
(f) the heavy chain variable region has an amino acid sequence set forth in SEQ ID NO: 39, 40, 41 or 42, or an amino acid sequence having at least 90% identity to any one amino acid sequence set forth in SEQ ID NO: 39, 40, 41 or 42; and/or the light chain variable region has an amino acid sequence set forth in SEQ ID NO: 43, 44, 45 or 46, or an amino acid sequence having at least 90% identity to any one amino acid sequence set forth in SEQ ID NO: 43, 44, 45 or 46; or
(g) the heavy chain variable region has an amino acid sequence set forth in SEQ ID NO: 56, 57 or 58, or an amino acid sequence having at least 90% identity to any one amino acid sequence set forth in SEQ ID NO: 56, 57 or 58; and/or the light chain variable region has an amino acid sequence set forth in SEQ ID NO: 59, 60, 61, 62 or 63, or an amino acid sequence having at least 90% identity to any one amino acid sequence set forth in SEQ ID NO: 59, 60, 61, 62 or 63; or
(h) the heavy chain variable region has an amino acid sequence set forth in SEQ ID NO: 65, 66, 67 or 68, or an amino acid sequence having at least 90% identity to any one amino acid sequence set forth in SEQ ID NO: 65, 66, 67 or 68; and/or the light chain variable region has an amino acid sequence set forth in SEQ ID NO: 69, 70, 71, 72, 73, 74, 75 or 76, or an amino acid sequence having at least 90% identity to any one amino acid sequence set forth in SEQ ID NO: 69, 70, 71, 72, 73, 74, 75 or 76.

### Claim 6 (depends on 1)

The antibody drug conjugate according to claim 1, wherein the anti-CEA antibody is a humanized antibody comprising a framework region derived from a human antibody or a framework region variant thereof, and the framework region variant has reverse mutations of up to 10 amino acids in a light chain framework region and/or a heavy chain framework region of the human antibody;
preferably, the framework region variant is selected from any one of the following (i) to (l):
(i) a framework region of the light chain variable region comprising a LCDR1, a LCDR2 and an LCDR3 having sequences set forth in SEQ ID NO: 24, SEQ ID NO: 25 and SEQ ID NO: 26, respectively, comprising one or more amino acid reverse mutations selected from the group consisting of 2V, 42G, 44V and 71Y, and/or a framework region of the heavy chain variable region comprising a HCDR1 having a sequence set forth in SEQ ID NO: 21, a HCDR2 having a sequence set forth in SEQ ID NO: 22 or SEQ ID NO: 47 and a HCDR3 having a sequence set forth in SEQ ID NO: 23, comprising one or more amino acid reverse mutations selected from the group consisting of 66K, 67A, 69L, 71V, 73K, 82F and 82AR:
(j) a framework region of the light chain variable region comprising a LCDR1, a LCDR2 and a LCDR3 having sequences set forth in SEQ ID NO: 18, SEQ ID NO: 19 and SEQ ID NO: 20, respectively, comprising one or more amino acid reverse mutations selected from the group consisting of 46P, 47W, 49Y, 70S and 71Y, and/or a framework region of the heavy chain variable region comprising a HCDR1 having a sequence set forth in SEQ ID NO: 15, a HCDR2 having a sequence set forth in SEQ ID NO: 16 or SEQ ID NO: 38 and a HCDR3 having a sequence set forth in SEQ ID NO: 17, comprising one or more amino acid reverse mutations selected from the group consisting of 38K and 46K;
(k) a framework region of the light chain variable region comprising a LCDR1, a LCDR2 and a LCDR3 having sequences set forth in SEQ ID NO: 30, SEQ ID NO: 31 and SEQ ID NO: 32, respectively, comprising one or more amino acid reverse mutations selected from the group consisting of 3V, 43P and 58V, and/or a framework region of the heavy chain variable region comprising a HCDR1, a HCDR2 and a HCDR3 having sequences set forth in SEQ ID NO: 27, SEQ ID NO: 28 and SEQ ID NO: 29, comprising one or more amino acid reverse mutations selected from the group consisting of 38K, 66K and 71V; and
(l) a framework region of the light chain variable region comprising a LCDR1 having a sequence set forth in SEQ ID NO: 35, a LCDR2 having a sequence set forth in SE ID NO: 36 or SEQ ID NO: 64 and a LCDR3 having a sequence set forth in SEQ ID NO: 37, comprising one or more amino acid reverse mutations selected from the group consisting of 4V, 36Y, 43P, 47V, 49E, 70D and 871; and/or a framework region of the heavy chain variable region comprising a HCDR1 having a sequence set forth in SEQ ID NO: 33, a HCDR2 having a sequence set forth in SEQ ID NO: 16 or SEQ ID NO: 38 and a HCDR3 having a sequence set forth in SEQ ID NO: 34, comprising one or more amino acid reverse mutations selected from the group consisting of the group consisting of 2I, 38K and 46K;
wherein sites of the reverse mutations are numbered according to Kabat numbering scheme.

### Claim 7 (depends on 1)

The antibody drug conjugate according to claim 1, wherein the anti-CEA antibody or the antigen-binding fragment thereof comprises a heavy chain constant region and a light chain constant region of the antibody; preferably, the heavy chain constant region is selected from the group consisting of human IgG1, IgG2, IgG3 and IgG4 constant regions and conventional variants thereof, and the light chain constant region is selected from the group consisting of human antibody κ and λ chain constant regions and conventional variants thereof; more preferably, the antibody comprises a heavy chain constant region having a sequence set forth in SEQ ID NO: 77 and a light chain constant region having a sequence set forth in SEQ ID NO: 78 or SEQ ID NO: 79; and
most preferably, the anti-CEA antibody comprises:
(m) a heavy chain having a sequence set forth in SEQ ID NO: 80 or a sequence having at least 85% identity thereto, and/or a light chain having a sequence set forth in SEQ ID NO: 81 or a sequence having at least 85% identity thereto;
(n) a heavy chain having a sequence set forth in SEQ ID NO: 82 or a sequence having at least 85% identity thereto, and/or a light chain having a sequence set forth in SEQ ID NO: 83 or a sequence having at least 85% identity thereto;
(o) a heavy chain having a sequence set forth in SEQ ID NO: 84 or a sequence having at least 85% identity thereto, and/or a light chain having a sequence set forth in SEQ ID NO: 85 or a sequence having at least 85% identity thereto; or
(p) a heavy chain having a sequence set forth in SEQ ID NO: 86 or a sequence having at least 85% identity thereto, and/or a light chain having a sequence set forth in SEQ ID NO: 87 or a sequence having at least 85% identity thereto.

### Claim 8 (depends on 1)

The antibody drug conjugate according to claim 1, wherein the antibody drug conjugate is an antibody drug conjugate of general formula (Pc-L-Y-D):
wherein:
Y is selected from the group consisting of —O—(CRaRb)m—CR1R2—C(O)—, —O—CR1R2—(CRaRb)m—, —O—CR1R2—, —NH—(CRaRb)m—CR1R2—C(O)— and —S—(CRaRb)m—CR1R2—C(O)—;
Ra and Rb are identical or different and are each independently selected from the group consisting of hydrogen, deuterium, halogen, alkyl, haloalkyl, deuterated alkyl, alkoxy, hydroxy, amino, cyano, nitro, hydroxyalkyl, cycloalkyl and heterocyclyl; or, Ra and Rb, together with carbon atoms connected thereto, form cycloalkyl and heterocyclyl;
R1 is selected from the group consisting of halogen, haloalkyl, deuterated alkyl, cycloalkyl, cycloalkylalkyl, alkoxyalkyl, heterocyclyl, aryl and heteroaryl; R2 is selected from the group consisting of hydrogen, halogen, haloalkyl, deuterated alkyl, cycloalkyl, cycloalkylalkyl, alkoxyalkyl, heterocyclyl, aryl and heteroaryl; or, R1 and R2, together with carbon atoms connected thereto, form cycloalkyl or heterocyclyl;
or, Ra and R2, together with carbon atoms connected thereto, form cycloalkyl or heterocyclyl;
m is an integer from 0 to 4;
n is a decimal or an integer from 1 to 10; preferably n is an integer or a decimal from 2 to 8, more preferably n is from 4 to 6:
L is a linker unit;
Pc is the anti-CEA antibody or the antigen-binding fragment thereof according to claim 1.

### Claim 9

(canceled)

### Claim 10 (depends on 8)

The antibody drug conjugate according to claim 8, wherein:
Y is —O—(CRaRb)m—CR1R2—C(O)—;
Ra and Rb are identical or different and are each independently selected from the group consisting of hydrogen, deuterium, halogen and alkyl;
R1 is haloalkyl or C3-6 cycloalkyl;
R2 is selected from the group consisting of hydrogen, haloalkyl and C3-6 cycloalkyl;
or, R1 and R2, together with carbon atoms connected thereto, form C3-6 cycloalkyl;
m is 0 or 1;
preferably;
wherein Y is selected from the group consisting of:
wherein the O terminus of Y is connected to the linker unit L.

### Claim 11

(canceled)

### Claim 12 (depends on 8)

The antibody drug conjugate according to claim 8, wherein the antibody drug conjugate is an antibody drug conjugate of general formula (Pc-L-D):
wherein:
L is a linker unit;
Pc is an anti-CEA antibody or an antigen-binding fragment thereof;
n is a decimal or an integer from 1 to 10.

### Claim 13 (depends on 8)

The antibody drug conjugate according to claim 8, wherein the linker unit -L- is -L1-L2-L3-L4-, wherein
L1 is selected from the group consisting of -(succinimidyl-3-yl-N)—W—C(O)—, —CH2—C(O)—NR3—W—C(O)— and —C(O)—W—C(O)—, wherein W is selected from the group consisting of C1-8 alkyl, C1-8 alkyl-cycloalkyl and linear heteroalkyl of 1 to 8 atoms, and the heteroalkyl comprises 1 to 3 heteroatoms selected from the group consisting of N, O and S, wherein the C1-8 alkyl, C1-8 alkyl-cycloalkyl and linear heteroalkyl of 1 to 8 atoms are each independently optionally further substituted with one or more substituents selected from the group consisting of halogen, hydroxy, cyano, amino, alkyl, chloroalkyl, deuterated alkyl, alkoxy and cycloalkyl;
L2 is selected from the group consisting of —NR4(CH2CH2O)p1CH2CH2C(O)—, —NR4(CH2CH2O)p1CH2C(O)—, —S(CH2)p1C(O)— and a chemical bond, wherein p1 is an integer from 1 to 20;
L3 is a peptide residue consisting of 2 to 7 amino acids, wherein the amino acids are selected from the group consisting of amino acid residues formed from amino acids from phenylalanine, glycine, valine, lysine, citrulline, serine, glutamic acid and aspartic acid, and are optionally further substituted with one or more substituents selected from the group consisting of halogen, hydroxy, cyano, amino, alkyl, chloroalkyl, deuterated alkyl, alkoxy and cycloalkyl;
L4 is selected from the group consisting of —NR5(CR6R7)t—, —C(O)NR5—, —C(O)NR5(CH2)t— and a chemical bond, wherein t is an integer from 1 to 6;
R3, R4 and R5 are identical or different and are each independently selected from the group consisting of hydrogen, alkyl, haloalkyl, deuterated alkyl and hydroxyalkyl;
R6 and R7 are identical or different and are each independently selected from the group consisting of hydrogen, halogen, alkyl, haloalkyl, deuterated alkyl and hydroxyalkyl.

### Claim 14 (depends on 8)

The antibody drug conjugate according to claim 8, wherein the linker unit -L- is -L1-L2-L3-L4-, wherein
L1 is
and s1 is an integer from 2 to 8;
L2 is a chemical bond;
L3 is a tetrapeptide residue; preferably, L3 is a tetrapeptide residue of glycine-glycine-phenylalanine-glycine (GGFG, SEQ ID NO: 92);
L4 is —NR5(CR6R7)t—, wherein R5, R6 and R7 are identical or different and are each independently hydrogen or alkyl, and t is 1 or 2;
wherein the L1 terminus is connected to Pc, and the L4 terminus is connected to Y;
preferably,
wherein -L- is:

### Claim at position 15

15-17. (canceled)

### Claim 18 (depends on 8, 13)

The antibody drug conjugate according to claim 8, wherein the antibody drug conjugate is an antibody drug conjugate of general formula (Pc-Lb-Y-D):
wherein:
s1 is an integer from 2 to 8;
Pc, R1, R2, R5-R7, m and n are as defined in claim 13.

### Claim 19 (depends on 8)

The antibody drug conjugate according to claim 8, wherein the antibody drug conjugate is selected from the group consisting of:
wherein Pc and n are as defined in claim 8.

### Claim 20 (depends on 8)

The antibody drug conjugate according to claim 8, wherein the antibody drug conjugate is selected from the group consisting of:
Hu63-13-2-A
wherein n is as defined in claim 8;
Hu63-13 comprises a heavy chain having a sequence set forth in SEQ ID NO: 80, and a light chain having a sequence set forth in SEQ ID NO: 81;
Hu47-14 comprises a heavy chain having a sequence set forth in SEQ ID NO: 82, and a light chain having a sequence set forth in SEQ ID NO: 83;
Hu67-14 comprises a heavy chain having a sequence set forth in SEQ ID NO: 84, and a light chain having a sequence set forth in SEQ ID NO: 85;
Hu103-32 comprises a heavy chain having a sequence set forth in SEQ ID NO: 86, and a light chain having a sequence set forth in SEQ ID NO: 87.

### Claim 21

(canceled)

### Claim 22 (depends on 1)

A pharmaceutical composition comprising the antibody drug conjugate according to claim 1 and one or more pharmaceutically acceptable excipients, diluents or carriers.

### Claim 23 (depends on 1, 22)

A method of treating a CEA-mediated disease or condition in a subject in need thereof, the method comprising administrating to the subject, the antibody drug conjugate according to claim 1 or the pharmaceutical composition according to claim 22.

### Claim 24 (depends on 23)

The method according to claim 23, wherein the CEA-mediated disease or condition is a cancer with high CEA expression.

### Claim 25 (depends on 1, 22)

A method of treating a cancer in a subject in need thereof, the method comprising administering to the subject, an effective amount of the antibody drug conjugate according to claim 1 or the pharmaceutical composition according to claim 22.

### Claim 26 (depends on 25)

The method according to claim 25, wherein the cancer is head and neck squamous cell carcinoma, head and neck cancer, brain cancer, neuroglioma, glioblastoma multiforme, neuroblastoma, central nervous system carcinoma, neuroendocrine tumor, throat cancer, nasopharyngeal cancer, esophageal cancer, thyroid cancer, malignant pleural mesothelioma, lung cancer, breast cancer, liver cancer, hepatobiliary cancer, pancreatic cancer, stomach cancer, gastrointestinal cancer, intestinal cancer, colon cancer, colorectal cancer, kidney cancer, clear cell renal cell carcinoma, ovarian cancer, endometrial cancer, cervical cancer, bladder cancer, prostate cancer, testicular cancer, skin cancer, melanoma, leukemia, lymphoma, bone cancer, chondrosarcoma, myeloma, multiple myeloma, myelodysplastic syndrome, Krukenberg tumor, myeloproliferative tumor, squamous cell carcinoma, Ewing's sarcoma, systemic light chain amyloidosis or Merkel cell carcinoma; more preferably, the lymphoma is selected from the group consisting of: Hodgkin's lymphoma, non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, primary mediastinal large B-cell lymphoma, mantle cell lymphoma, small lymphocytic lymphoma, large B-cell lymphoma rich in T-cells/histiocytes and lymphoplasmacytic lymphoma, the lung cancer is selected from the group consisting of non-small cell lung cancer and small cell lung cancer, and the leukemia is selected from the group consisting of: chronic myeloid leukemia, acute myeloid leukemia, lymphocytic leukemia, lymphoblastic leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia or myeloid cell leukemia